Screener
Halozyme Therapeutics HALO Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock - $0.001 par value; 300,000 shares authorized; 114,042 and 117,782 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 114 | 118 |
| Additional paid-in capital | — | 12,002 |
| Accumulated other comprehensive loss | (7,830) | (18,092) |
| Retained earnings | 151,259 | 54,786 |
| Total stockholders’ equity | 143,543 | 48,814 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's common stock?
- Halozyme Therapeutics (HALO) reported common stock of 300M in Q2 2026.
- How has Halozyme Therapeutics's common stock changed year-over-year?
- Halozyme Therapeutics's common stock decreased by 0.0% year-over-year, from 300M to 300M.
- What is the long-term trend for Halozyme Therapeutics's common stock?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from 300M to 300M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Halozyme Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude